An investigational monoclonal antibody targeting TNF-like ligand 1A (TL1A), known as duvakitug, has shown a “robust” clinical response in patients with Crohn’s disease and ulcerative colitis, according to trial data reported by Healio and summarised in Nature Reviews Gastroenterology & Hepatology. The findings are relevant to UK clinicians managing patients with inflammatory bowel disease (IBD) who have exhausted or not yet tried advanced biologic therapies.
Background Context
TL1A is a signalling protein involved in immune activation and tissue fibrosis, and has emerged as a therapeutic target distinct from the tumour necrosis factor and interleukin pathways already addressed by existing biologics. Many patients with Crohn’s disease or ulcerative colitis lose response to current advanced therapies over time, or fail to respond at all, creating ongoing demand for treatments with new mechanisms of action. Duvakitug is being developed as an anti-TL1A monoclonal antibody, and its performance has been assessed in the phase 2b RELIEVE UCCD trial, led by Jairath and colleagues, which evaluated efficacy and safety in patients with Crohn’s disease and ulcerative colitis.
Key Findings
According to the reporting, duvakitug produced a consistent clinical response across two distinct patient groups: those who had previously been treated with advanced biologic or small molecule therapies, and those who were naive to such treatments. Healio’s coverage describes the response as “robust”, indicating that the drug’s effect was not confined to a more treatment-responsive, biologic-naive population, a pattern seen with some other agents in IBD trials. The RELIEVE UCCD phase 2b trial, cited by Nature Reviews Gastroenterology & Hepatology, assessed both efficacy and safety endpoints in Crohn’s disease, with parallel data presented for ulcerative colitis. The consistency of response regardless of prior treatment exposure is presented as a notable feature of the results, since many existing therapies show reduced efficacy in patients who have already cycled through other biologics.
Clinical Relevance
For gastroenterologists and IBD nurses in the UK, a therapy that performs comparably in both treatment-naive and previously treated patients could offer an additional option for those with limited remaining choices, a group increasingly discussed at specialist meetings as a distinct and growing clinical challenge. While duvakitug remains investigational and is not yet available for routine prescribing, its TL1A mechanism represents a potential addition to the treatment landscape alongside existing anti-TNF, anti-integrin, and interleukin-targeted therapies. Continued trial data will be needed to establish its longer-term safety and place in treatment pathways.
Reference
Relieving IBD with duvakitug. Nat Rev Gastroenterol Hepatol. 2026. doi:10.1038/s41575-026-01251-3
This article is a journalistic summary for informational purposes only. It does not constitute clinical advice or a recommendation to alter treatment decisions.